Tobias Polak

Chapter 4 72 2 Incomplete redaction Supplementary Figure 3: Redacted estimates (ICER, cost) from TA487: Venetoclax for treating chronic lymphocytic leukaemia. Table from the Public Committee Slides Appraisal Consultation. Supplementary Figure 4: Redacted estimates (QALY, cost) from TA491: Ibrutinib for treating Waldenström macroglobulinemia. Table from Evidence Review Group Report.

RkJQdWJsaXNoZXIy MTk4NDMw